ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1464

Utility of Relative Cardiovascular Risk Score Scales and Vascular Age Predictors in Patients with Reumathoid Arthritis UNDER 50 YEARS of Age

Andrea Zacarias1, Carmen Gomez Vaquero2, Francisco Javier Narváez3, Joan Miquel Nolla4, Miguel Angel González-Gay5, Carlos González-Juanatey6 and Javier Llorca7, 1Hospital Universitari de Bellvitge, Barcelona, Spain, 2Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, 4Rheumatology, Bellvitge University Hospital, Barcelona, Spain, 5Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, 6Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, 7Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, rheumatoid arthritis (RA) and risk management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid Arthritis (RA) is associated with a greater cardiovascular mortality than the general population of the same age and gender. Cardiovascular events prediction scales, due to its significant dependence on age, underestimate absolute cardiovascular risk (CVR) in young people. Two methods exist to address this problem: a) Cardiovascular Relative Risk, which estimates the increased risk when compared to people of the same age without CVRF. B) Vascular age, defined as the lower age with the same absolute CVR but with no CVRF. OBJECTIVE: To evaluate the utility of the relative cardiovascular risk score scales and the vascular age predictors in patients with RA, younger than 50 years of age.

Methods:  Transversal prospective study developed at the Rheumatology Services in two Spanish academic hospitals. Only patients under 50 years of age who fulfilled the EULAR/ACR 2010 criteria for RA were included. They were selected consecutively when they came on regular follow-up. We registered to calculate SCORE, REGICOR, Relative Cardiovascular Risk and Vascular Age (age, gender, tobacco habits, systolic blood pressure, total serum cholesterol concentration and HDL and diabetes Mellitus). According to the EULAR 2011 recommendations, a multiplying factor of 1,5 was applied to SCORE, REGICOR and Relative Cardiovascular Risk in patients who fitted in at least two of the following criteria: a) Duration of RA > 10 years, b) positive RF or CCP , c) Presence of extra-articular manifestations.

Results: 140 patients with RA under 50 years of age were included [120 (86%) women] with an mean age of 40 ± 7 years. 64% of patients had RF+ and 56% CCP+. Regarding to EULAR multiplying factors, 30% had RA duration > 10 years, 71% had CCP or RF+, 11% had extra-articular manifestations, and 26% had 2 or more factors. None of the patients had has a previous history of cardiovascular events. The modified (after the application of the multiplying fact) mean SCORE was 1,03 ± 0,52 and modified REGICOR 1,81 ± 1,37. Mean Cardiovascular relative risk was 2,05 ± 1,33 between 2x and 10x. 54% of the patients had a relative cardiovascular risk superior to 1, and 47% had cardiovascular relative risk between 2 and 3 times higher. Mean vascular Age’s was of 44 ± 10 years, 4 years more than biological age. 41% of patients, vascular age was greater than biological age, from 3 to 20 years older. Relative Cardiovascular risk identifies more patients with CVR than Vascular Age. Patients with increased relative cardiovascular risk were older (41 ± 6 vs 38 ± 9 years; p < 0,01) and had been diagnosed with RA for over10 years (40% vs 7%, p < 0,001).

Conclusion:  In young patients with Rheumatoid Arthritis, the estimates of Relative Cardiovascular Risk and the assessment of vascular age allow us to identify patients with an increased cardiovascular risk, who may be overlooked by SCORE event prediction charts.


Disclosure: A. Zacarias, None; C. Gomez Vaquero, None; F. J. Narváez, None; J. M. Nolla, None; M. A. González-Gay, None; C. González-Juanatey, None; J. Llorca, None.

To cite this abstract in AMA style:

Zacarias A, Gomez Vaquero C, Narváez FJ, Nolla JM, González-Gay MA, González-Juanatey C, Llorca J. Utility of Relative Cardiovascular Risk Score Scales and Vascular Age Predictors in Patients with Reumathoid Arthritis UNDER 50 YEARS of Age [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/utility-of-relative-cardiovascular-risk-score-scales-and-vascular-age-predictors-in-patients-with-reumathoid-arthritis-under-50-years-of-age/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-relative-cardiovascular-risk-score-scales-and-vascular-age-predictors-in-patients-with-reumathoid-arthritis-under-50-years-of-age/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology